RT Journal Article
SR Electronic
T1 Human DC3 Antigen Presenting Dendritic Cells from Induced Pluripotent Stem Cells
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.06.22.449451
DO 10.1101/2021.06.22.449451
A1 Taiki Satoh
A1 Marcelo A. S. Toledo
A1 Janik Boehnke
A1 Kathrin Olschok
A1 Niclas Flosdorf
A1 Katrin Götz
A1 Caroline Küstermann
A1 Stephanie Sontag
A1 Kristin Seré
A1 Steffen Koschmieder
A1 Tim H. Brümmendorf
A1 Nicolas Chatain
A1 Yoh-ichi Tagawa
A1 Martin Zenke
YR 2021
UL http://biorxiv.org/content/early/2021/06/22/2021.06.22.449451.abstract
AB Dendritic cells (DC) are professional antigen-presenting cells that develop from hematopoietic stem cells. Different DC subsets exist based on ontogeny, location and function, including the recently identified proinflammatory DC3 subset. DC3 have the prominent activity to polarize CD8+ T cells into CD8+ CD103+ tissue resident T cells. Here we describe human DC3 differentiated from induced pluripotent stem cells (iPS cells). iPS cell-derived DC3 have the gene expression and surface marker make-up of blood DC3 and polarize CD8+ T cells into CD8+ CD103+ tissue-resident memory T cells in vitro. To test the impact of malignant JAK2 V617F mutation on DC3, we differentiated patient-specific iPS cells with JAK2 V617Fhet and JAK2 V617Fhom mutations into JAK2 V617Fhet and JAK2 V617Fhom DC3. The JAK2 V617F mutation enhanced DC3 production and caused a bias towards erythrocytes and megakaryocytes. The patient-specific iPS cell-derived DC3 are expected to allow studying DC3 in human diseases and developing novel therapeutics.Competing Interest StatementThe authors have declared no competing interest.